Pharming Narrows FY2026 Sales Guidance from $375.000M-$395.000M to $380.000M-$390.000M vs $389.333M Est
Benzinga Newsdesk 1 week ago
NewsGuidance
Pharming (NASDAQ:PHAR) narrows FY2026 sales outlook from $375.000 million-$395.000 million to $380.000 million-$390.000 million vs $389.333 million estimate.
Pharming (NASDAQ:PHAR) narrows FY2026 sales outlook from $375.000 million-$395.000 million to $380.000 million-$390.000 million vs $389.333 million estimate.